GlassScriptPhysician profile
Surendra Kelwala
NPI 1558475517
$1,225.58
in general payments reported to CMS, 2019-2025
13 companies · $153 in 2025
The $153 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $212 · 2020: $68.40 · 2021: $173 · 2022: $154 · 2023: $184 · 2024: $282 · 2025: $153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $618.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $618.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $287.10 | 2021-2024 | |
| Neurocrine Biosciences, INC. | $225.28 | 2019-2024 | Ingrezza |
| Axsome Therapeutics, INC. | $121.83 | 2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $116.76 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $113.76 | 2020-2025 | Austedo Xr |
| Supernus Pharmaceuticals, INC. | $81.20 | 2021-2022 | |
| Orexo US, INC. | $79.41 | 2019-2021 | |
| Alkermes, INC. | $67.31 | 2022-2025 | Aristada, Lybalvi |
| Allergan, INC. | $48.60 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.97 | 2019-2020 | |
| Lundbeck LLC | $28.22 | 2019-2023 | Rexulti |
| Indivior INC. | $14.05 | 2021 | |
| Janssen Pharmaceuticals, INC | $12.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Surendra Kelwala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.